Trial Profile
Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ciltacabtagene autoleucel (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 13 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2018 New trial record